Its unique dual receptor action often results in better glycemic control compared to medications that target just one receptor
SGLT2 inhibitors (such as empagliflozin, dapagliflozin, or canagliflozin) are particularly recommended for patients with established cardiovascular disease, heart failure, or chronic kidney disease
Sustained Weight Loss Most patients see 15 to 20 percent body weight reduction over 12 to 18 months with semaglutide or tirzepatide, paired with our structured monitoring program
If partially breastfeeding: If youre considering restarting GLP-1s and are still partially breastfeeding, thats a decision that really needs a conversation with your OB/GYN or your babys pediatrician
Semaglutide changed how I nourish my bodyand I've never felt better
Long-Term Considerations For individuals needing ongoing support in maintaining healthy habits, continuing semaglutide at a lower maintenance dosage is a viable option with minimal long-term risks
